The multicenter randomized phase III trial JCOG2405 (ELDER-WEEKLY) was conducted to compare the efficacy and safety of weekly cisplatin given concurrently with radiotherapy versus radiotherapy alone in elderly patients with head and neck squamous cell carcinoma (HNSCC) who were considered unfit for high‑dose cisplatin. The trial title and design are reported in Jpn J Clin Oncol and indexed with PMID 42341154 and DOI 10.1093/jjco/hyag097.
JCOG2405 is described in the source as a multicenter, randomized, phase III clinical trial. The registered trial name, ELDER-WEEKLY, indicates a focus on an older patient population and use of a weekly cisplatin regimen as the investigational concomitant chemotherapy strategy. The provided content does not include the detailed protocol, randomization ratio, blinding status, or dates of enrollment.
The source specifies the target population as elderly patients with head and neck squamous cell carcinoma who were judged unfit for high‑dose cisplatin. Beyond this general description, the excerpt does not report the precise inclusion or exclusion criteria, age cutoffs, performance status limits, comorbidity specifications, tumor stage distribution, or HPV/p16 status for oropharyngeal cancers.
The intervention arm is summarized as weekly cisplatin delivered with radiotherapy; the control arm is radiotherapy alone. The source does not provide dosing details for cisplatin (such as mg/m2), number of weekly cycles planned, radiotherapy dose and fractionation, techniques used, or any supportive-care measures. Details on treatment modifications, dose reductions, or criteria for treatment discontinuation are not reported in the provided content.
The citation identifies the study as a randomized phase III trial comparing concurrent weekly cisplatin chemoradiotherapy to radiotherapy alone, implying evaluation of clinical efficacy and safety. However, the source excerpt does not report the trial's primary endpoint(s) (for example overall survival, progression‑free survival, locoregional control, or toxicity), nor does it present any efficacy or adverse‑event results. No numerical outcomes, hazard ratios, confidence intervals, p‑values, or safety profiles are available in the content provided.
While the trial is identified as phase III and randomized, the source does not report statistical planning details such as planned sample size, power calculations, interim analyses, stratification factors, or the statistical methods used for primary and secondary endpoints.
The published article lists multiple authors and institutional affiliations. Lead and contributing investigators include Kota Kawabata, Koichi Yasuda, Satoaki Nakamura, Yoshitaka Honma, Ryusuke Suzuki, Yuri Ueda, Satoshi Saito, Kazuto Matsuura, Nobuhiro Hanai, Naoki Nakamura, Junki Mizusawa, Keita Sasaki, Haruhiko Fukuda, Takashi Mizowaki, and Naomi Kiyota. The corporate authors include the Head and Neck Cancer Study Group and the Radiation Therapy Study Group of the Japan Clinical Oncology Group.
Affiliated institutions named in the source include the Japan Clinical Oncology Group Data Center/Operations Office at the National Cancer Center Hospital (Tokyo) and multiple university and cancer center departments across Japan (Hokkaido University Hospital; Kansai Medical University; Tokyo Medical University; National Cancer Center Hospital East; Aichi Cancer Center Hospital; St. Marianna University School of Medicine; Kyoto University Graduate School of Medicine; Kobe University Hospital).
The article is published in the Japanese Journal of Clinical Oncology with citation details: 2026 Oct 8;56(10):1272–1279. It is indexed in PubMed with PMID 42341154 and has DOI 10.1093/jjco/hyag097. The PubMed entry for the article is available and the full text link is provided in the original source entry.
The PubMed excerpt supplied here contains bibliographic, author and affiliation information and the trial title but does not provide the trial abstract text or the detailed results. Specifically, the following were not reported in the provided content and therefore cannot be summarized from this source: exact eligibility criteria, demographic and disease characteristics of enrolled patients, cisplatin and radiotherapy dosing and schedules, primary and secondary endpoints, efficacy outcomes, toxicity data, statistical analyses and conclusions. Any interpretation of efficacy, safety, or practice implications cannot be made from the present excerpt.
If you would like, I can retrieve or summarize the full abstract or full text (where available) to extract the protocol details and outcome data; the current summary is limited to the bibliographic and high‑level design elements explicitly presented in the PubMed entry.